Authors

Latest:

Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS

Latest:

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO

Latest:

MRD Testing and the Role of Revumenib in Treatment Response

Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.

June-Wha Rhee, MD

Latest:

Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.

Jane Lowe Meisel, MD

Latest:

Dr Meisel on the Impact of Endocrine Therapy–Related Toxicities on QOL in ER+/HER2– Breast Cancer

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.

Usman Ali Akbar, MD

Latest:

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Kai-Keen Shiu, MD

Latest:

Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Chad Tang, MD

Latest:

Dr Tang on Unanswered Questions About the Role of Radiation Therapy in RCC

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Pavani Chalasani, MD, University of Arizona Cancer Center

Latest:

“Breast Cancer Talk” Review of Data from the SABCS 2020 Virtual Meeting

Chan Cheah, MBBS

Latest:

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Ashley Ross, MD, PhD, Northwestern Medicine

Latest:

Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Zosia Piotrowska, MD, MHS

Latest:

Dr Piotrowska on the Importance of Genomic Profiling to Identify HER2 Mutations in NSCLC

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

Jason Brayer, MD, PhD

Latest:

Dr. Brayer on the Promise of BiTEs in Multiple Myeloma

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

AdventHealth Cancer Institute

Latest:

Novel Detection Methods May End Chemotherapy for Patients With CRC

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.

Danielle E. Marcotulli, APN, John Theurer Cancer Center

Latest:

Evolving Treatment Landscape of Myelofibrosis

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.

Anant Ramaswamy, MD

Latest:

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Coral O. Omene, MD, PhD

Latest:

Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

The Ohio State University Comprehensive Cancer Center

Latest:

Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.

Emil Lou, MD, PhD, FACP

Latest:

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Melinda Krigel

Latest:

UCSF Prostate Cancer Program Awarded SPORE Grant by National Cancer Institute

Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.